100 related articles for article (PubMed ID: 445322)
1. Actinomycin-D, levamisole chemoimmunotherapy of refractory malignant melanoma.
Hall SW; Benjamin RS; Lewinski U; Mavligit G
Cancer; 1979 Apr; 43(4):1195-200. PubMed ID: 445322
[TBL] [Abstract][Full Text] [Related]
2. Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
Samson MK; Baker LH; Talley RW; Fraile RJ; McDonald B
Cancer Treat Rep; 1978 Aug; 62(8):1223-5. PubMed ID: 356980
[TBL] [Abstract][Full Text] [Related]
3. Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
Robidoux A; Gutterman JU; Bodey GP; Hersh EM
Cancer; 1982 Jun; 49(11):2246-51. PubMed ID: 7042068
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study.
Costanzi JJ; Fletcher WS; Balcerzak SP; Taylor S; Eyre HJ; O'Bryan RM; Al-Sarraf M; Frank J
Cancer; 1984 Feb; 53(4):833-6. PubMed ID: 6362830
[TBL] [Abstract][Full Text] [Related]
5. Dibromodulcitol (DBD), DTIC, and actinomycin-D in disseminated malignant melanoma. A phase I-II clinical trial.
Samson MK; Haas CD; Baker LH; Cummings G
Am J Clin Oncol; 1985 Apr; 8(2):167-71. PubMed ID: 3834791
[TBL] [Abstract][Full Text] [Related]
6. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
7. Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma.
Creagan ET; Schutt AJ; Long HJ; Green SJ
Med Pediatr Oncol; 1986; 14(2):86-7. PubMed ID: 3713642
[TBL] [Abstract][Full Text] [Related]
8. Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
Ramseur WL; Richards F; Muss HB; Rhyne L; Cooper MR; White DR; Stuart JJ; Spurr CL
Cancer Treat Rep; 1978 Jul; 62(7):1085-7. PubMed ID: 356970
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma.
Mulder NH; Sleijfer DT; Smit JM; De Vries EG; Willemse PH; Koops HS
Eur J Cancer Clin Oncol; 1986 Jul; 22(7):879-81. PubMed ID: 2429842
[TBL] [Abstract][Full Text] [Related]
10. Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma.
Thatcher N; Wagstaff J; Mene A; Smith D; Orton C; Craig P
Eur J Cancer Clin Oncol; 1986 Aug; 22(8):1009-14. PubMed ID: 3770045
[TBL] [Abstract][Full Text] [Related]
11. Single-dose dacarbazine and dactinomycin in advanced malignant melanoma.
Hochster H; Levin M; Speyer J; Dunleavy S; Harris M; Roses D; Golomb F; Muggia F
Cancer Treat Rep; 1985 Jan; 69(1):39-42. PubMed ID: 3967259
[TBL] [Abstract][Full Text] [Related]
12. Actinomycin D in the treatment of advanced breast cancer.
Grimm RA; Muss HB; White DR; Richards F; Cooper MR; Stuart JJ; Jackson DV; Barnes PL; Spurr CL
Cancer Chemother Pharmacol; 1980; 4(3):195-7. PubMed ID: 7397943
[TBL] [Abstract][Full Text] [Related]
13. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T
J Clin Oncol; 1992 Dec; 10(12):1919-26. PubMed ID: 1280673
[TBL] [Abstract][Full Text] [Related]
14. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
Atkins MB; O'Boyle KR; Sosman JA; Weiss GR; Margolin KA; Ernest ML; Kappler K; Mier JW; Sparano JA; Fisher RI
J Clin Oncol; 1994 Aug; 12(8):1553-60. PubMed ID: 8040667
[TBL] [Abstract][Full Text] [Related]
15. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
16. [Combination chemotherapy of disseminated skin melanoma with nitrosomethylurea].
Perevodchikova NJ; Moros LW; Kogonia LM
Arch Geschwulstforsch; 1986; 56(4):273-81. PubMed ID: 3530176
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of the efficacy of imidazole-carboxamide and of a combination of nitrosomethylurea, vincristine and dactinomycin in disseminated melanoma].
Kogoniia LM; Moroz LV; Perevodchikova NI; Platinskiĭ LV; Borisov AI
Vopr Onkol; 1981; 27(4):16-21. PubMed ID: 7015692
[TBL] [Abstract][Full Text] [Related]
18. A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.
Ahmed FY; Leonard GA; A'Hern R; Taylor AE; Lorentzos A; Atkinson H; Moore J; Nicolson MC; Riches PG; Gore ME
Br J Cancer; 1996 Oct; 74(7):1109-13. PubMed ID: 8855983
[TBL] [Abstract][Full Text] [Related]
19. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N
J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study.
Beretta G; Bonadonna G; Cascinelli N; Morabito A; Veronesi U
Cancer Treat Rep; 1976 Jan; 60(1):33-40. PubMed ID: 1000518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
